Recurrent Head and Neck Squamous Cell Carcinoma Clinical Trials in Portland, Oregon

5 studies are recruiting for recurrent head and neck squamous cell carcinoma in Portland, Oregon right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

   This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary s…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Providence Portland Medical Center, Portland, Oregon

   Locations

   199 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06589804 on ClinicalTrials.gov

2. Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

   This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Oregon Health and Science University, Portland, Oregon

   Locations

   11 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06980038 on ClinicalTrials.gov

3. Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

   This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy [cisplatin and carboplatin] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head …

   Stage

   Phase 2

   Ages

   18 to 79

   Site

   Providence Portland Medical Center, Portland, Oregon

   Locations

   178 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04671667 on ClinicalTrials.gov

4. FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

   Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, r…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Site #0113, Portland, Oregon

   Locations

   203 in total

   Run by

   Bicara Therapeutics

   See if you can join NCT06788990 on ClinicalTrials.gov

5. Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

   This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   OHSU Knight Cancer Institute, Portland, Oregon

   Run by

   OHSU Knight Cancer Institute

   See if you can join NCT07405086 on ClinicalTrials.gov